GERD 9: PPI-Refractory Heartburn and Series Synthesis

Episode keywords: PPI refractory GERD workup, Spechler NEJM 2019 GERD trial, functional heartburn proportion, fundoplication refractory GERD outcomes, ACG refractory GERD algorithm, GERD diagnosis algorithm, desipramine GERD, baclofen refractory heartburn, systematic GERD workup

Episode Summary

The Spechler NEJM 2019 trial enrolled 366 patients with heartburn persisting on PPIs and systematically worked up every one before randomizing anyone. The result: only 21% had truly PPI-resistant, reflux-related heartburn. More than one in four had functional heartburn with no reflux relationship. Eleven percent responded to PPI optimization alone before the workup even started. The trial shows that systematic evaluation is not a prerequisite for surgery -- it is the treatment. This final episode covers the trial data, the ACG refractory GERD algorithm, and a full synthesis of all nine episodes into the framework boards are actually testing.

Key Topics

• Spechler et al., NEJM 2019: VA study, 366 patients with heartburn persisting on PPI therapy. Step 1: optimize PPI to omeprazole 20 mg twice daily taken 30 to 60 minutes before breakfast and dinner for two weeks. Result: 42 patients (11.5%) responded to optimized PPI alone, never reaching the formal workup. Step 2: the non-responders underwent endoscopy with biopsies, esophageal manometry, and combined impedance-pH monitoring on PPI therapy. Final distribution: 70 patients (19%) unable or unwilling to complete workup; 54 (15%) excluded for miscellaneous reasons; 21 (6.3%) had non-GERD esophageal disorders; 99 (27%) had functional heartburn (normal acid exposure, negative SAP); and 78 (21%) had truly PPI-resistant reflux-related heartburn. One in five patients. That is the denominator for surgical candidates.
• Randomized comparison in confirmed reflux-related refractory heartburn: 78 patients randomized to three arms. Laparoscopic Nissen fundoplication achieved 67% treatment success (at least 50% improvement in GERD-HRQL at one year). Active medical therapy (omeprazole plus baclofen plus desipramine) achieved 28%. Control medical therapy (omeprazole plus placebo baclofen plus placebo desipramine) achieved 12%. Surgery was significantly superior to both medical arms. For the correctly diagnosed patient, fundoplication works. The implication: if you had operated on all 366 patients without the workup, you would have operated on the 27% with functional heartburn, the 11.5% who just needed proper PPI instructions, and the 6.3% with non-GERD disorders. Systematic evaluation is what makes surgery successful, not surgery itself.
• ACG algorithm for refractory GERD: Step 1 -- optimize PPI (correct timing, twice daily, consistent use). Step 2 -- endoscopy. If normal endoscopy and no prior objective GERD confirmation, proceed to ambulatory pH monitoring off PPIs. Step 3 -- if GERD is established and symptoms persist on twice-daily PPI, proceed to combined impedance-pH monitoring on PPIs. For extraesophageal symptoms, antireflux procedures require objective reflux evidence before proceeding.

GERD 8: pH Monitoring, Impedance, and Diagnosing Refractory GERD

Episode keywords: ambulatory pH monitoring GERD, wireless Bravo pH capsule, impedance pH monitoring MII-pH, symptom index reflux, symptom association probability SAP, on versus off PPI pH testing, reflux hypersensitivity diagnosis, acid exposure time normal values, combined impedance pH refractory GERD

Episode Summary

The decision to test on or off PPIs is the most important single judgment call in reflux monitoring, and it follows directly from one question: has GERD been objectively confirmed before? This episode covers the three monitoring platforms (catheter pH, wireless Bravo, combined impedance-pH), the specific clinical scenarios that call for each, the on-versus-off PPI algorithm, and the SI and SAP metrics including their well-documented limitations.

Key Topics

• Indications for ambulatory reflux monitoring: Two broad scenarios. First, heartburn persisting despite optimized PPI therapy where objective characterization is needed. Second, GERD diagnosis has never been objectively established and empiric PPI therapy is being questioned. Atypical presentations (chest pain without heartburn, isolated cough, laryngeal symptoms) also warrant testing when typical GERD symptoms are absent.
• Catheter pH monitoring: pH electrode placed transnasally, positioned 5 cm above the LES, records 24 hours. Measures acid exposure time (percentage of recording period with pH below 4). Abnormal above 6%. Normal below 4%. Indeterminate (grey zone) between 4 and 6%. Foundation platform for reflux diagnosis.
• Wireless Bravo pH monitoring: Capsule clipped to esophageal mucosa during endoscopy, transmits pH wirelessly. Records 48 to 96 hours versus 24, improving diagnostic yield because day-to-day reflux variability is captured. Better patient tolerance means more representative activity patterns. Limitation: measures acid only, no impedance capability.
• Combined impedance-pH monitoring (MII-pH): Nasal catheter with impedance sensors plus a pH electrode. Impedance principle: liquid has low electrical impedance (conducts electricity), air has high impedance. Retrograde liquid bolus produces a characteristic impedance drop propagating proximally. The pH electrode classifies each reflux event as acidic, weakly acidic, or non-acidic. Detects all reflux regardless of acidity -- critical for testing patients on PPI therapy, where acid is suppressed but reflux events still occur at pH-neutral values.
• The on-versus-off PPI decision: If GERD has NOT been objectively established (no prior positive pH study, no prior LA-C or D esophagitis, no documented Barrett's), test OFF PPIs after at least 7 days of discontinuation. The question is whether pathologic reflux exists at all. Testing on PPIs risks false-negative acid suppression. If GERD IS established (prior positive pH study, long-segment Barrett's, prior LA-C or D esophagitis), and symptoms persist on twice-daily PPI, test ON PPIs with combined impedance-pH. The question is why established GERD is not responding. Is there breakthrough acid? Non-acidic reflux with symptom correlation? Or no reflux-symptom association at all? Note: LA-A does not establish GERD. LA-B is borderline. Only LA-C and D represent confirmed erosive disease.
• Symptom Index (SI): Number of symptom episodes within a defined time window of a reflux event divided by total symptom episodes. SI above 50% is positive. Simple but does not account for the baseline probability of overlap when reflux events are very frequent.
• Symptom Association Probability (SAP): Divides the 24-hour recording into 720 two-minute intervals. Marks each for reflux occurrence and symptom report. Applies Fisher's exact test. SAP above 95% is positive. Statistically more sophisticated and adjusts for baseline co-occurrence probability.
• Limitations of both metrics: No study has demonstrated SAP provides better clinical information than SI in predicting treatment outcomes. They frequently disagree. Both depend on patients accurately pressing a symptom button in real time. Both use arbitrary time windows to define association. Neither has been validated as a strong predictor of antireflux therapy response. Boards expect you to know the formulas and cutoffs AND to know these limitations.
• RCT evidence for impedance-pH: A randomized controlled trial demonstrated that treatment decisions guided by impedance-pH results produced better outcomes than empiric management in PPI-refractory heartburn. This moved combined impedance-pH from research tool to evidence-based clinical recommendation for the on-PPI testing scenario.

Board Pearls

GERD 7: NERD -- Non-Erosive Reflux Disease

Episode keywords: non-erosive reflux disease NERD, functional heartburn definition, reflux hypersensitivity, GERD normal endoscopy, dilated intercellular spaces GERD histology, basal zone hyperplasia esophagus, PPI failure categories, EoE masked by PPI, Rome IV functional heartburn

Episode Summary

Up to 70% of GERD patients have no visible mucosal breaks on endoscopy. NERD is not mild GERD or questionable GERD; it is the majority phenotype, with real pathologic acid exposure and real histologic correlates. This episode covers why a normal endoscopy on PPIs cannot classify a patient as NERD, the four categories of PPI failure and why getting the category right determines treatment success, the histology of NERD including a mechanistic revision to the dilated intercellular spaces model, and the treatment distinctions between NERD, reflux hypersensitivity, and functional heartburn.

Key Topics

• NERD definition: Troublesome reflux-related symptoms in the absence of endoscopically visible mucosal breaks. Pathologic acid exposure or positive symptom-reflux correlation is present. NERD is not "no GERD" -- it is a distinct phenotype within the GERD spectrum.
• Clinical diagnosis without endoscopy: The ACG states that a patient with typical heartburn who responds completely to acid suppression has a clinical diagnosis of GERD without requiring endoscopy. Endoscopy in this population is for Barrett's screening, not to confirm GERD.
• The NERD misclassification trap: To classify a patient as NERD, endoscopy must be performed off PPIs. A normal endoscopy while on active PPI therapy does not establish NERD -- it may simply mean the PPI healed existing erosions. This is also the scenario where EoE can be missed: PPIs suppress EoE features (rings, furrows, eosinophilic infiltration) completely. The guideline recommendation is to stop PPIs 2 to 4 weeks before endoscopy when EoE is a diagnostic consideration.
• Four categories of PPI failure: Category 1 -- the problem is not esophageal (cardiac chest pain, biliary disease masquerading as heartburn). Category 2 -- esophageal but not GERD (EoE causing chest pain and dysphagia, achalasia producing regurgitation labeled as reflux). Category 3 -- reflux-related, but either acid is genuinely persisting despite PPI (timing, adherence, or PPI-resistant acid production) OR physiologically normal reflux is perceived as painful (reflux hypersensitivity). Category 4 -- functional heartburn (no temporal relationship between symptoms and reflux events, normal acid exposure, negative symptom association). Treatment is completely different for each category.
• NERD histology: Elongated papillae (finger-like lamina propria projections extending beyond two-thirds of epithelial thickness), basal zone hyperplasia (proliferative layer exceeding 15% of epithelial thickness), and inflammatory cell infiltration consistent with the cytokine-mediated injury model from Episode 1. Dilated intercellular spaces (DIS) are visible on both electron microscopy and standard H&E staining; mean intercellular space diameter is measurably greater in NERD patients versus controls.
• DIS mechanism revision: The traditional explanation was that acid and pepsin directly damage tight junctions, increasing paracellular permeability. More recent data suggests cytokine-induced damage to mucosal microvasculature causes vascular fluid extravasation into intercellular spaces. The mechanism is inflammatory vascular leakage, not acid dissolving cell adhesion.
• Reflux hypersensitivity: Normal acid exposure time on ambulatory pH monitoring but positive symptom-reflux association (positive SI or SAP). The reflux is physiologic; the perception is pathologic. Rome IV classifies this as a functional esophageal disorder driven by peripheral or central visceral sensitization. Treatment shifts toward neuromodulators. More acid suppression will not help because acid quantity is not the problem.
• PPI response in NERD: Approximately 37% symptomatic response at 4 weeks versus 56% in erosive GERD. However, this gap is largely explained by study contamination: NERD trials often failed to exclude functional heartburn patients, who by definition will not respond to acid suppression. Baclofen may help patients where non-acidic reflux plays a prominent role.

Board Pearls

GERD 6: Pregnancy, Atypical GERD, and the LPR Controversy

Episode keywords: GERD in pregnancy, famotidine pregnancy GERD, LPR laryngopharyngeal reflux controversy, extraesophageal GERD symptoms, PPI safety pregnancy, laryngeal erythema nonspecific, LPS LPRD consensus terminology, empiric PPI atypical symptoms

Episode Summary

Two-thirds of pregnant women experience heartburn, and the treatment hierarchy is strictly ordered. But the more contentious territory is what happens when reflux is blamed for laryngeal, pharyngeal, and pulmonary symptoms. A recent consensus conference recommended retiring the term "laryngopharyngeal reflux" and replacing it with a framework that separates symptoms from proven disease. Laryngoscopic findings of erythema are found in over 90% of healthy controls, which means the most common tool used to diagnose LPR has essentially no specificity. This episode covers why PPIs do not reliably help extraesophageal symptoms without concurrent typical GERD, and when objective reflux testing is required before treatment.

Key Topics

• GERD in pregnancy -- step-up approach: Heartburn affects approximately two-thirds of pregnant women. Progesterone relaxes the LES; growing uterus increases intra-abdominal pressure. Treatment order: (1) lifestyle modifications and smaller meals; (2) antacids (aluminum, calcium, magnesium-based are safe) and alginates; (3) sucralfate (not systemically absorbed); (4) H2 receptor antagonists if needed, with famotidine preferred for breastfeeding patients due to lowest breast milk concentration; (5) PPIs as next step if required.
• PPI safety in pregnancy -- historical category distinction: Under the former FDA letter system, all PPIs were category B except omeprazole, which was category C (animal studies showed some adverse effect without adequate human data). The FDA has since retired letter categories in favor of descriptive labeling, but boards still test this historical distinction. Omeprazole was the sole category C PPI. Esomeprazole strontium and magnesium-containing formulations should be avoided in pregnancy and lactation. Vonoprazan has no adequate pregnancy data; manufacturer advises against breastfeeding while taking it.
• Atypical and extraesophageal GERD presentations: Chronic laryngitis, chronic cough, asthma exacerbation, globus sensation, sore throat, burning tongue, dental erosions, chronic sinusitis, and non-heartburn chest pain. Two mechanisms: direct contact (acid reaches the larynx, which is far more acid-sensitive than the esophagus) and vagally mediated reflexes (acid in the distal esophagus triggers cough or bronchospasm without reaching the throat).
• The LPR terminology shift: A recent consensus conference recommends retiring "laryngopharyngeal reflux (LPR)" as a diagnosis. The new framework distinguishes laryngopharyngeal symptoms (LPS, the clinical presentation: cough, voice changes, throat clearing, phlegm sensation) from laryngopharyngeal reflux disease (LPRD, which requires objective evidence that reflux is causing those symptoms). Laryngoscopy cannot establish LPRD.
• Laryngoscopic findings are nonspecific: Laryngeal erythema and edema attributed to acid damage are found in over 90% of healthy normal controls. A positive laryngoscopy for reflux changes has virtually no specificity. What laryngoscopy does accomplish is excluding other oropharyngeal pathology (vocal cord lesions, masses, structural abnormalities) rather than confirming a reflux etiology.
• The data problem: Approximately 50% of patients carrying an LPR diagnosis have normal acid exposure on conventional ambulatory pH monitoring. Proximal esophageal and pharyngeal pH monitoring have consistently failed to distinguish suspected LPR patients from healthy controls.
• PPI response for extraesophageal symptoms: Non-cardiac chest pain with objective evidence of acid reflux responds well (56 to 85% benefit). For throat clearing, hoarseness, and chronic cough without concomitant typical GERD, randomized placebo-controlled trials have not shown consistent PPI benefit over placebo. The AGA advises against empiric PPI trials for extraesophageal symptoms without concomitant typical GERD symptoms. ACG recommends non-GERD causes be evaluated first (ENT for hoarseness, pulmonology and upper airway cough syndrome workup for cough) and reflux testing performed before initiating PPI therapy when typical GERD is absent. When extraesophageal symptoms accompany daily heartburn, an 8 to 12 week trial of twice-daily PPI is reasonable.
• Surgery for extraesophageal symptoms: Only consider antireflux surgery or endoscopic antireflux procedures in patients with objective evidence of reflux. Fundoplication does not reliably improve laryngopharyngeal symptoms in patients already failing PPI therapy. If PPIs (which dramatically reduce acid) are not helping, acid is likely not the cause, and mechanical prevention of reflux will not help either.

Board Pearls

GERD 5: Antireflux Surgery, Magnetic Sphincter Augmentation, and Endoscopic Therapies

Episode keywords: Nissen fundoplication GERD, Toupet partial fundoplication, laparoscopic antireflux surgery, LINX magnetic sphincter augmentation, Roux-en-Y gastric bypass GERD, sleeve gastrectomy GERD worsening, transoral incisionless fundoplication TIF, antireflux surgery outcomes, GERD surgery recurrence

Episode Summary

Fundoplication is not just a sphincter tightening. Each surgical step corrects a specific pathophysiologic defect in the antireflux barrier. This episode walks through the four steps of fundoplication and what each one does mechanically, the distinction between full and partial wraps and when each is appropriate, the critical interaction between morbid obesity and surgical choice, the LINX device's specific niche, and the evidence base for endoscopic antireflux therapies including TIF.

Key Topics

• Fundoplication -- four steps and their mechanisms: (1) Creating an intra-abdominal esophageal segment returns the distal esophagus to the positive-pressure abdominal environment, where elevated abdominal pressure squeezes the esophagus shut rather than promoting reflux. (2) Hiatal hernia reduction eliminates the intrathoracic reservoir that re-refluxes its contents. (3) Crural approximation re-establishes skeletal muscle buttressing of the LES. (4) Fundic wrap narrows the angle of His (restoring the flap valve), acts as a one-way mechanical valve, and prevents fundal distention that would otherwise trigger TLESRs. Boards test each of these mechanisms individually.
• Wrap types: Nissen is 360 degrees with the strongest antireflux effect and the most side effects (dysphagia, gas-bloat syndrome, inability to belch or vomit). Toupet is posterior 270 degrees. Dor is anterior 180 degrees. Partial wraps have less antireflux efficacy but fewer obstructive side effects and are preferred when esophageal peristalsis is impaired.
• IEM and wrap selection: If manometry shows ineffective esophageal motility, a Nissen wrap creates a high-pressure zone that weak peristalsis cannot overcome, resulting in post-operative dysphagia. Manometry before fundoplication is standard of care precisely to identify this. Many surgeons choose Toupet in patients with documented IEM.
• Long-term outcomes: Swedish Patient Registry data from 2,655 fundoplication patients showed 17.7% reflux recurrence at mean 5.1 years follow-up. Fundoplication is effective but not permanent. Risk factors for recurrence include female sex, older age, and comorbidity. Patients should understand that long-term PPI use may still be necessary.
• Morbid obesity and surgical choice: In patients with BMI greater than 35, fundoplication has a higher failure rate due to persistent mechanical stress from elevated intra-abdominal pressure and ongoing visceral adiposity effects. Roux-en-Y gastric bypass is the preferred operation for GERD in morbidly obese patients. It addresses both reflux (small gastric pouch, Roux limb diverting bile and pancreatic secretions) and obesity simultaneously. Sleeve gastrectomy converts the stomach to a high-pressure tube, removes the fundus, disrupts the angle of His, and causes or worsens GERD. De novo GERD after sleeve gastrectomy is a recognized complication. If the board presents a morbidly obese patient with significant GERD considering bariatric surgery, the answer is Roux-en-Y, not sleeve.
• LINX magnetic sphincter augmentation: A ring of titanium beads with magnetic cores placed laparoscopically around the distal esophagus. Magnetic attraction maintains closure; swallowing force temporarily separates beads. Preserves ability to belch and vomit in most patients. No randomized comparison to fundoplication exists; uncontrolled studies show comparable results. One randomized trial compared LINX to optimized medical therapy and showed MSA superiority for regurgitation control. ACG recommends MSA as an alternative to fundoplication specifically for regurgitation-predominant patients failing medical therapy. Contraindications include large hiatal hernias and certain MRI requirements (though newer designs are MRI-conditional).
• Endoscopic antireflux therapies: Stretta delivers radiofrequency energy to the LES area; results are mixed and guidelines offer limited endorsement. Transoral incisionless fundoplication (TIF) with the EsophyX device creates a partial fundoplication endoscopically with no abdominal incisions. Randomized trials show TIF efficacy for regurgitation. ACG recommends considering TIF for troublesome regurgitation or heartburn without severe esophagitis (LA-C or D) and without hiatal hernia larger than 2 cm. Anti-reflux mucosectomy (ARMS) uses EMR at the cardia to create submucosal fibrosis that tightens the EGJ; data predominantly from Asian centers; promising but not yet established in US practice.

Board Pearls

GERD 4: Acid Suppression -- PPIs, P-CABs, and the Vonoprazan Revolution

Episode keywords: PPI mechanism of action, vonoprazan P-CAB GERD, omeprazole equivalents potency, parietal cell proton pump H+K+ATPase, PPI safety evidence, H2 blocker tachyphylaxis, nocturnal acid breakthrough, CYP2C19 PPI metabolism, Laine vonoprazan trial 2023

Episode Summary

Not all PPIs are equal, and vonoprazan is a different class of drug rather than a stronger PPI. This episode traces acid secretion from parietal cell stimulus to proton pump activation, explains why PPIs require meal timing while vonoprazan does not, quantifies potency differences across PPIs using omeprazole equivalents, and covers the Laine 2023 trial showing vonoprazan's superiority in severe erosive esophagitis. PPI safety associations from observational data are contrasted with the randomized controlled trial evidence, which largely exonerates the class.

Key Topics

• Parietal cell physiology and the final common pathway: Three stimulants activate the proton pump. Gastrin binds CCK-2 receptors and raises intracellular calcium. Histamine binds H2 receptors and raises cAMP. Acetylcholine binds M3 receptors and raises calcium. Both calcium and cAMP trigger fusion of tubulovesicles with the canalicular membrane, exposing active H+/K+-ATPase pumps. H2 blockers interrupt only one of three pathways. PPIs and vonoprazan block the pump directly, downstream of all three stimulants regardless of what is activating the cell.
• H2 receptor antagonists: Available agents are cimetidine, famotidine, and nizatidine. Ranitidine was withdrawn due to NDMA (N-nitrosodimethylamine) nitrosamine contamination. H2 blockers relieve symptoms in 50 to 67% of patients. Healing rates for esophagitis are poor compared to PPIs. Tachyphylaxis limits long-term utility. Best role is mild intermittent GERD or as a bedtime add-on for nocturnal acid breakthrough, though tachyphylaxis also limits that indication over time.
• PPI mechanism and meal timing: PPIs are acid-labile prodrugs requiring enteric coating. After duodenal absorption, they enter the parietal cell canalicular space, get protonated in the acidic environment, and form covalent disulfide bonds with cysteine residues on active proton pumps. Only actively secreting pumps are accessible; tubulovesicle-bound pumps are invisible to PPIs. Taking PPIs 30 to 60 minutes before a meal ensures the drug arrives when the meal is stimulating maximum pump activation. Plasma half-life is approximately 90 minutes. Full steady-state suppression requires 3 to 5 days of dosing as successive pumps are inactivated. PPIs are NOT effective for acute breakthrough symptoms -- this is a board trap.
• CYP2C19 metabolism: Most PPIs are metabolized by CYP2C19. Poor metabolizers achieve higher drug levels and better suppression. Rapid metabolizers may have subtherapeutic levels at standard doses. Rabeprazole is least affected by CYP2C19 polymorphisms due to more non-enzymatic conversion.
• Omeprazole equivalents (potency at standard doses): Setting omeprazole 20 mg as 1.00: lansoprazole 15 mg is 0.90; esomeprazole 20 mg is 1.60; rabeprazole 20 mg is 1.82 (most potent standard PPI); pantoprazole 20 mg is 0.23 (roughly one-quarter the acid suppression of omeprazole 20 mg). Pantoprazole's widespread use reflects formulary economics and IV availability, not pharmacologic superiority.
• Nocturnal acid breakthrough: 70 to 80% of patients on twice-daily PPI still have gastric pH below 4 for more than one hour overnight. Clinical significance is often unclear -- many are asymptomatic and healing well. A bedtime H2 blocker can help short-term but tachyphylaxis limits durability. Intervention is warranted primarily when associated with persistent symptoms or non-healing esophagitis.
• PPI safety -- RCT evidence: Moayyedi et al., Gastroenterology 2019, randomized 17,598 patients to pantoprazole versus placebo over 3 years. No significant differences in fractures, dementia, CKD, cardiovascular events, or pneumonia. Enteric infections were modestly higher (1.4% vs 1.0%, OR 1.33). The vast majority of observational safety signals disappear when patients are properly randomized, reflecting residual confounding in population studies. Hypomagnesemia has the strongest mechanistic basis and is a class effect; monitor magnesium in long-term PPI users with symptoms or risk factors.
• Vonoprazan mechanism: Acid-stable, active drug (not a prodrug). No enteric coating needed. Faster absorption. Binds H+/K+-ATPase through ionic interactions with very high affinity. Critically, binds both active AND inactive pumps -- does not require a secreting pump. Half-life 7 to 9 hours versus 90 minutes for PPIs. Not significantly affected by CYP2C19 polymorphisms. Does not require meal timing. Achieves acid suppression on day 1 rather than days 3 to 5.
• Laine et al., Gastroenterology 2023: 1,024 patients with erosive esophagitis randomized to vonoprazan 20 mg versus lansoprazole 30 mg over 8 weeks. Overall healing: 92.9% vs 84.6% (noninferior and superior). LA-C and D subgroup: 91.7% vs 72.0%, a 19.6 percentage point difference. Vonoprazan also superior for maintenance of healing. Potency context: vonoprazan 10 mg daily approximates omeprazole 60 mg; vonoprazan 20 mg approximates omeprazole 60 mg twice daily.

Board Pearls

GERD 3: Acid Pocket, Endoscopy, and the Initial Approach

Episode keywords: acid pocket GERD, LA classification reflux esophagitis, Barrett's esophagus screening ACG AGA, empiric PPI trial, alarm symptoms GERD, non-erosive reflux disease endoscopy, lifestyle modifications GERD, alginates GERD mechanism

Episode Summary

The acid pocket explains why Barrett's esophagus develops specifically at the GEJ rather than randomly throughout the esophagus. This episode covers the postprandial acid pocket and its role in genotoxic injury, the LA classification of reflux esophagitis and which grades actually confirm GERD, why only 30% of heartburn patients have visible esophagitis, the ACG versus AGA Barrett's screening criteria, and the full initial management approach including lifestyle modifications and the pharmacologic options before PPIs.

Key Topics

• The acid pocket: After meals, a layer of newly secreted, unbuffered acid sits on top of gastric contents at the cardia. The Z-line (squamocolumnar junction) is exposed to this acid for more than 10% of the day even in healthy people. In hiatal hernia, the acid pocket migrates above the diaphragm. Dietary nitrate is concentrated in saliva, swallowed, and reduced to nitrite by oral bacteria. When nitrite contacts the acid pocket, it generates nitric oxide and reactive nitrogen species that are genotoxic. The GEJ is therefore simultaneously exposed to acid-peptic injury and nitrosative stress. This dual insult drives intestinal metaplasia at the cardia specifically.
• Three questions endoscopy answers in GERD: Is there reflux esophagitis? Is there a peptic stricture? Is there Barrett's esophagus? Endoscopy does not confirm GERD in a patient with typical symptoms and complete PPI response. That is a clinical diagnosis.
• LA classification: Grade A is mucosal breaks less than 5 mm not extending between fold tops. Grade B is mucosal breaks greater than 5 mm not extending between fold tops. Grade C extends between two or more fold tops but involves less than 75% of circumference. Grade D involves 75% or more of circumference. Grades B through D confirm GERD. Grade A has poor interobserver agreement and can be seen in asymptomatic individuals; it alone does not definitively confirm pathologic reflux.
• The 30% statistic: Only about 30% of patients with frequent heartburn have endoscopic esophagitis. The majority have non-erosive reflux disease. Heartburn severity does not predict esophagitis severity. Symptoms and mucosal damage are poorly correlated.
• Empiric PPI trial: For classic heartburn and regurgitation without alarm symptoms, start an 8-week empiric PPI trial taken 30 to 60 minutes before a meal. Do not scope first. Stop PPIs 2 to 4 weeks before any diagnostic endoscopy; active PPI therapy heals esophagitis and can also mask eosinophilic esophagitis.
• Alarm symptoms requiring endoscopy: Dysphagia, odynophagia, weight loss, GI bleeding, anemia, vomiting. These bypass empiric therapy.
• Barrett's screening -- ACG vs AGA: ACG recommends a single screening EGD for patients with chronic GERD symptoms plus three or more additional risk factors (male sex, age over 50, white race, tobacco use, obesity, family history of Barrett's or esophageal adenocarcinoma). ACG generally does not recommend screening women without multiple risk factors. AGA 2022 considers chronic GERD as one risk factor among many and recommends screening when three or more total risk factors are present, so a white male over 50 with obesity could qualify even without documented GERD symptoms.
• Lifestyle modifications (8 items boards test): Elevate head of bed 6 to 8 inches with blocks (not pillows). Lose weight. Avoid recumbency for 2 to 3 hours after meals. Avoid right-lateral decubitus sleeping (left-lateral keeps the acid pocket below the esophageal inlet). No bedtime snacks. Avoid trigger foods (chocolate, coffee, alcohol, fatty foods). No smoking or alcohol. Avoid medications that reduce LES pressure (calcium channel blockers, nitrates, anticholinergics, theophylline). Evidence for most is limited; weight loss and head-of-bed elevation have the strongest data.
• Other medical options: Alginates form a gel raft on top of gastric contents, physically displacing the acid pocket from the GEJ -- a direct mechanical intervention targeting pathophysiology. Prokinetics (metoclopramide) are no longer recommended; side effect rates approach 30%, including tardive dyskinesia. Baclofen reduces TLESRs but CNS side effects limit clinical utility.

Board Pearls

GERD 2: The Antireflux Barrier, Clearance, and Hiatal Hernia

Episode keywords: antireflux barrier, hiatal hernia reflux mechanism, esophageal clearance GERD, nocturnal acid reflux, H. pylori Barrett's inverse association, obesity GERD mechanism, IEM reflux esophagitis, angle of His flap valve

Episode Summary

The antireflux barrier has three components, esophageal clearance has four mechanisms, and hiatal hernia disrupts all of them simultaneously. This episode builds on the pathophysiology of Episode 1 to explain why hiatal hernia size correlates with reflux severity, why nighttime reflux is more injurious than daytime reflux, and two systemic factors that modify GERD risk through mechanisms boards specifically test: H. pylori and obesity.

Key Topics

• Three components of the antireflux barrier: The LES smooth muscle provides tonic pressure. The EGJ flap valve (angle of His) creates a geometric one-way valve that tightens when the fundus distends. The crural diaphragm provides skeletal muscle augmentation during inspiration and straining. All three can fail independently or together.
• Hill classification and AFS grading: The flap valve is graded endoscopically. Hill Grade I is a prominent fold closely approximating the scope. Hill Grade IV is no fold at all, a gaping hiatus. AFS Grade 1 indicates all components intact; higher grades indicate progressive failure.
• Four esophageal clearance mechanisms: Gravity, peristalsis, salivation, and submucosal gland bicarbonate secretion. During sleep, three of the four are eliminated simultaneously: the supine position removes gravity, swallowing frequency drops to near zero eliminating peristalsis, and salivation stops. Only submucosal secretion persists. This is why nocturnal reflux is disproportionately injurious.
• IEM and reflux esophagitis: Between 25 and 48% of reflux esophagitis patients have ineffective esophageal motility. IEM impairs clearance and is a risk factor for more severe disease. It is also the primary reason manometry is required before antireflux surgery. A weak esophagus wrapped with a 360-degree Nissen cannot generate sufficient peristaltic force and develops dysphagia.
• Hiatal hernia mechanics: Hernia separates the intrinsic LES from the crural diaphragm, displacing the LES into the negative-pressure thorax. The crura now squeeze around the stomach below the herniated segment, creating a reservoir that readily refluxes. Fundal distention of the herniated segment increases TLESR frequency. The angle of His widens as the hernia enlarges, destroying the flap valve. All three antireflux components fail simultaneously. Hernia size correlates with reflux severity.
• H. pylori and the inverse association: H. pylori causing predominantly corpus (fundic) gastritis leads to parietal cell atrophy and reduced acid production. Less acid means less esophageal injury. This creates an inverse association between H. pylori, Barrett's esophagus, and esophageal adenocarcinoma. Clinical policy: GI societies do NOT recommend routine H. pylori testing and treatment in GERD patients. GERD is NOT a contraindication to treating H. pylori when another indication exists. Do not withhold treatment for peptic ulcer disease because a patient has reflux.
• Obesity and GERD: Dose-dependent positive association with BMI. Visceral adipose tissue increases intragastric pressure, promotes hiatal hernia formation, and secretes adipokines that directly impair esophageal barrier integrity and dilate intercellular spaces. Obesity is also an independent risk factor for Barrett's and esophageal adenocarcinoma beyond its effect on reflux volume.

Board Pearls

GERD 1: Pathogenesis — It's Not Just Acid Burns

Episode keywords: GERD pathogenesis, cytokine-mediated esophageal injury, transient LES relaxation TLESR, GABA-B baclofen reflux, LES pressure GERD, nucleus tractus solitarius reflux, ACG GERD definition 2022

Episode Summary

The "acid burn" model of reflux esophagitis has been replaced. This episode covers the Dunbar JAMA 2016 paradigm shift showing that acid triggers a cytokine-mediated inflammatory response that builds from deep to superficial, not from the surface inward. It then establishes the two-component antireflux barrier, the neural control of transient LES relaxations, and one of the most consistently board-tested misconceptions: that most GERD patients have normal resting LES pressure.

Key Topics

• ACG 2022 GERD definition: Reflux of stomach contents causing troublesome symptoms and/or complications, objectively documented by endoscopy or ambulatory pH monitoring. Approximately 20% of Western adults report weekly heartburn.
• The cytokine-mediated injury model: Acid contacts esophageal epithelial cells, which secrete pro-inflammatory cytokines that recruit T lymphocytes. The damage is inflammatory, not chemical. Histologic consequence: basal cell hyperplasia and elongated papillae appear before surface erosions. Injury builds from inside out. This explains why symptom severity does not correlate with endoscopic severity.
• The two-component LES: The intrinsic LES is smooth muscle providing tonic contraction. The extrinsic LES is the crural diaphragm, skeletal muscle that dynamically augments pressure during inspiration and straining. Both components must be understood to explain hiatal hernia and fundoplication mechanics.
• TLESRs as the dominant reflux mechanism: Transient LES relaxations are sudden, prolonged relaxations not triggered by swallowing, lasting more than 10 seconds, representing the normal belch reflex. Controlled by the nucleus tractus solitarius in the medulla. Inhibited by GABA-B neurons, which is why baclofen (a GABA-B agonist) reduces TLESR frequency. CCK-1 receptors mediate intrinsic sphincter relaxation during TLESRs, connecting fatty meals to reflux through a defined pathway.
• The TLESR misconception: GERD patients do not have more TLESRs than normal people. The frequency is the same. What differs is that a higher proportion of TLESRs in GERD are associated with acid reflux rather than just gas venting. The problem is content, not frequency.
• LES pressure in GERD: Most GERD patients have normal resting LES pressure. Only patients with severe erosive esophagitis consistently have abnormally low LES pressure, generally below 10 mmHg. GERD is not simply a "weak sphincter" disease for the majority of patients.

Board Pearls

Motility 7: IEM, Opioid Effects, and Non-Cardiac Chest Pain

Episode keywords: ineffective esophageal motility IEM, scleroderma esophagus manometry, absent contractility, fundoplication IEM, opioid esophageal motility, opioid elevated IRP, non-cardiac chest pain algorithm, functional chest pain neuromodulators, Chicago Classification IEM criteria, visceral hypersensitivity esophagus

Episode Summary

The final episode closes the loop on the normal-IRP side of the Chicago Classification and ties the entire series together. Esophageal hypocontraction — from the scleroderma esophagus to IEM — has a critical intersection with surgical planning: weak peristalsis and a Nissen fundoplication is a mistake that manometry is specifically designed to prevent. The episode also covers opioid-induced esophageal dysfunction (the great mimicker of every motility diagnosis) and the evidence-based stepwise approach to non-cardiac chest pain.

Key Topics

• Scleroderma esophagus: Fibrosis and vascular obliteration damage esophageal smooth muscle. Manometric hypocontraction in ~80% of scleroderma patients. Weak clearance + hypotensive LES = severe GERD with impaired acid clearance. Not scleroderma-specific — identical findings in mixed connective tissue disease, RA, SLE, diabetes, amyloidosis, alcoholism, myxedema, MS, and longstanding GERD. "Scleroderma esophagus" should be reserved for patients with confirmed scleroderma.
• IEM — CCv4.0 criteria:
  • >70% of swallows ineffective (failed: DCI <100, OR weak: DCI 100–450, OR fragmented: peristaltic breaks >5 cm in 20 mmHg isobaric contour with DCI ≥450)
  • OR ≥50% of swallows outright failed (DCI <100)
  • Note: CCv3.0 required ≥50% failed or weak. CCv4.0 made this more stringent.
  • 100% failed peristalsis = Absent contractility — a separate, more severe diagnosis.
• IEM and fundoplication — the critical board intersection:
  • If a patient has IEM and you perform a Nissen (360° wrap), the weakly peristaltic esophagus cannot generate sufficient pressure to push a bolus through the tight wrap → post-operative dysphagia.
  • If IEM is present: use partial fundoplication (Toupet 270° posterior or Dor 180° anterior), or avoid fundoplication altogether.
  • This is the same principle as in achalasia — peristaltic impairment is a contraindication to complete wraps.
• Opioid-induced esophageal dysfunction:
  • Opioids can mimic nearly every HRM diagnosis: elevated IRP (EGJOO, achalasia-like), elevated DCI (hypercontractile), short DL (DES, Type III-like).
  • Opioids are in the explicit EGJOO differential and should be considered in any elevated-IRP pattern.
  • Rule: Before diagnosing ANY primary motility disorder on HRM, check the medication list for opioids. If opioids are present — discontinue (if possible) and repeat the study.
• Non-cardiac chest pain — the stepwise algorithm:
  1. Exclude cardiac, thoracic, and pancreaticobiliary causes first. Cardiology evaluation if needed.
  2. Check for alarm symptoms (dysphagia, weight loss, bleeding) → endoscopy if present.
  3. If no alarm features: check for typical GERD symptoms → endoscopy → pH monitoring if endoscopy normal.
  4. No alarm, no typical GERD symptoms → double-dose PPI trial for 2 months. Relief = GERD confirmed.
  5. PPI failure → esophageal manometry.
  6. Manometry shows motility disorder → treat per disorder-specific guidelines, add neuromodulator.
  7. Normal manometry → functional chest pain. Treat with neuromodulator (TCA, trazodone, SSRI) + cognitive behavioral therapy.
  • Data: Up to 70% of NCCP patients have typical GERD symptoms. Abnormal pH monitoring in 40–60%. ~80% of NCCP patients with abnormal pH or erosive esophagitis achieve pain relief with PPIs. Fewer than 30% have abnormal motility studies.

Board Pearls

Board trap: Opioid-using patient with HRM showing elevated IRP, premature contractions, and elevated DCI — do not diagnose achalasia + DES + hypercontractile esophagus. The answer is opioid-induced dysmotility.

High-yield: Non-cardiac chest pain algorithm — cardiac exclusion FIRST, then GERD evaluation, then PPI trial, then manometry. Jumping directly to manometry is wrong if the cardiac workup has not been completed.